Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Biogen Idec: Drug Approval Offers ‘Underappreciated Earnings Upside,” Morgan Stanley Says
Biogen Idec: Drug Approval Offers ‘Underappreciated Earnings Upside,” Morgan Stanley Says
Biogen Idec: Drug Approval Offers ‘Underappreciated Earnings Upside,” Morgan Stanley Says
Submitted by
admin
on August 18, 2014 - 11:52am
Source:
Barron's
News Tags:
earnings
Biogen Idec
MS
multiple sclerosis
Plegridy
Headline:
Biogen Idec: Drug Approval Offers ‘Underappreciated Earnings Upside,” Morgan Stanley Says
Do Not Allow Advertisers to Use My Personal information
